EMBECTA CORP. Research and Development Expense
EMBECTA CORP. (EMBC) reported Research and Development Expense of $5.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-07
- EMBECTA CORP. research and development expense for the quarter ending 2026-06-30 was $5.60M, a 27.27% increase year-over-year.
- EMBECTA CORP. research and development expense for the quarter ending 2026-03-31 was $5.40M, a 32.50% decline year-over-year.
- EMBECTA CORP. research and development expense for the quarter ending 2025-12-31 was $4.60M, a 77.34% decline year-over-year.
- EMBECTA CORP. research and development expense for the quarter ending 2025-09-30 was $4.60M, a 76.77% decline year-over-year.
- EMBECTA CORP. research and development expense for fiscal 2025 was $37.30M, a 52.66% decline from fiscal 2024.
- EMBECTA CORP. research and development expense for fiscal 2024 was $78.80M, a 7.51% decline from fiscal 2023.
- EMBECTA CORP. research and development expense for fiscal 2023 was $85.20M, a 27.35% increase from fiscal 2022.
- EMBECTA CORP. research and development expense for fiscal 2022 was $66.90M, a 5.69% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.60M 10-Q · filed 2026-08-07 | $11.00M derived: sum of 2 quarters · filed 2026-08-07 | $15.60M 10-Q · filed 2026-08-07 | $20.20M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $5.40M 10-Q · filed 2026-05-05 | $10.00M 10-Q · filed 2026-05-05 | $14.60M derived: sum of 3 quarters · filed 2026-05-05 | $19.00M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $4.60M 10-Q · filed 2026-02-05 | $9.20M derived: sum of 2 quarters · filed 2026-02-05 | $13.60M derived: sum of 3 quarters · filed 2026-08-07 | $21.60M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-09-30 | $4.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $9.00M derived: sum of 2 quarters · filed 2026-08-07 | $17.00M derived: sum of 3 quarters · filed 2026-08-07 | $37.30M 10-K · filed 2025-11-25 |
| 2025-06-30 | $4.40M 10-Q · filed 2026-08-07 | $12.40M derived: sum of 2 quarters · filed 2026-08-07 | $32.70M 10-Q · filed 2026-08-07 | $52.50M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $8.00M 10-Q · filed 2026-05-05 | $28.30M 10-Q · filed 2026-05-05 | $48.10M derived: sum of 3 quarters · filed 2026-05-05 | $68.50M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $20.30M 10-Q · filed 2026-02-05 | $40.10M derived: sum of 2 quarters · filed 2026-02-05 | $60.50M derived: sum of 3 quarters · filed 2026-02-05 | $78.90M derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-09-30 | $19.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $40.20M derived: sum of 2 quarters · filed 2025-11-25 | $58.60M derived: sum of 3 quarters · filed 2025-11-25 | $78.80M 10-K · filed 2025-11-25 |
| 2024-06-30 | $20.40M 10-Q · filed 2025-08-08 | $38.80M derived: sum of 2 quarters · filed 2025-08-08 | $59.00M 10-Q · filed 2025-08-08 | $82.60M derived: sum of 4 quarters · filed 2025-11-25 |
| 2024-03-31 | $18.40M 10-Q · filed 2025-05-09 | $38.60M 10-Q · filed 2025-05-09 | $62.20M derived: sum of 3 quarters · filed 2025-11-25 | $84.80M derived: sum of 4 quarters · filed 2025-11-25 |
| 2023-12-31 | $20.20M 10-Q · filed 2025-02-06 | $43.80M derived: sum of 2 quarters · filed 2025-11-25 | $66.40M derived: sum of 3 quarters · filed 2025-11-25 | $88.50M derived: sum of 4 quarters · filed 2025-11-25 |
| 2023-09-30 | $23.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $46.20M derived: sum of 2 quarters · filed 2025-11-25 | $68.30M derived: sum of 3 quarters · filed 2025-11-25 | $85.20M 10-K · filed 2025-11-25 |
| 2023-06-30 | $22.60M 10-Q · filed 2024-08-09 | $44.70M derived: sum of 2 quarters · filed 2024-08-09 | $61.60M 10-Q · filed 2024-08-09 | $79.50M derived: sum of 4 quarters · filed 2024-12-11 |
| 2023-03-31 | $22.10M 10-Q · filed 2024-05-09 | $39.00M 10-Q · filed 2024-05-09 | $56.90M derived: sum of 3 quarters · filed 2024-12-11 | $71.20M derived: sum of 4 quarters · filed 2024-12-11 |
| 2022-12-31 | $16.90M 10-Q · filed 2024-02-09 | $34.80M derived: sum of 2 quarters · filed 2024-12-11 | $49.10M derived: sum of 3 quarters · filed 2024-12-11 | $67.10M derived: sum of 4 quarters · filed 2024-12-11 |
| 2022-09-30 | $17.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-11 | $32.20M derived: sum of 2 quarters · filed 2024-12-11 | $50.20M derived: sum of 3 quarters · filed 2024-12-11 | $66.90M 10-K · filed 2024-12-11 |
| 2022-06-30 | $14.30M 10-Q · filed 2023-08-08 | $32.30M derived: sum of 2 quarters · filed 2023-08-08 | $49.00M 10-Q · filed 2023-08-08 | $68.50M derived: sum of 4 quarters · filed 2023-11-29 |
| 2022-03-31 | $18.00M 10-Q · filed 2023-05-12 | $34.70M 10-Q · filed 2023-05-12 | $54.20M derived: sum of 3 quarters · filed 2023-11-29 | $69.90M derived: sum of 4 quarters · filed 2023-11-29 |
| 2021-12-31 | $16.70M 10-Q · filed 2023-02-14 | $36.20M derived: sum of 2 quarters · filed 2023-11-29 | $51.90M derived: sum of 3 quarters · filed 2023-11-29 | $66.00M derived: sum of 4 quarters · filed 2023-11-29 |
| 2021-09-30 | $19.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-29 | $35.20M derived: sum of 2 quarters · filed 2023-11-29 | $49.30M derived: sum of 3 quarters · filed 2023-11-29 | $63.30M 10-K · filed 2023-11-29 |
| 2021-06-30 | $15.70M 10-Q · filed 2022-08-15 | $29.80M derived: sum of 2 quarters · filed 2022-08-15 | $43.80M 10-Q · filed 2022-08-15 | |
| 2021-03-31 | $14.10M 10-Q · filed 2022-05-13 | $28.10M 10-Q · filed 2022-05-13 | ||
| 2020-12-31 | $14.00M 10-Q · filed 2022-03-16 | |||
| 2020-09-30 | $61.40M 10-K · filed 2022-12-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |